Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SZC Effect on Tacrolimus and Cyclosporin PK in Healthy Subjects
NCT04788641Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sodium zirconium cyclosilicate in hyperkalemia (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Maximum Observed Concentration at 72 hours and Area Under Concentration-time Curve From Time Zero to Infinity at 72 hours. Started Mar 2021; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT04788641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04788641.